Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

F. Neumann, T. Graef, C. Tapprich, M. Vaupel, Ulrich G. Steidl, U. Germing, R. Fenk, A. Hinke, R. Haas, G. Kobbe

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings. Mycophenolate Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited. We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n = 33), myelodysplastic syndrome (MDS) (n = 3), acute lymphoblastic leukemia (ALL) (n = 20) or chronic myeloid leukemia (n = 37) who received CSA/MMF (n = 26) or CSA/MTX (n = 67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings. No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD. Time to myeloid recovery was significantly shorter in patients who received CSA/MMF. We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings.

Original languageEnglish (US)
Pages (from-to)1089-1093
Number of pages5
JournalBone Marrow Transplantation
Volume35
Issue number11
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Mycophenolic Acid
Stem Cell Transplantation
Graft vs Host Disease
Methotrexate
Cyclosporine
Siblings
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Therapeutics
Survival Rate
Recurrence
Mortality

Keywords

  • Cyclosporine
  • GVHD
  • Methotrexate
  • Mycophenolate Mofetil
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. / Neumann, F.; Graef, T.; Tapprich, C.; Vaupel, M.; Steidl, Ulrich G.; Germing, U.; Fenk, R.; Hinke, A.; Haas, R.; Kobbe, G.

In: Bone Marrow Transplantation, Vol. 35, No. 11, 06.2005, p. 1089-1093.

Research output: Contribution to journalArticle

Neumann, F. ; Graef, T. ; Tapprich, C. ; Vaupel, M. ; Steidl, Ulrich G. ; Germing, U. ; Fenk, R. ; Hinke, A. ; Haas, R. ; Kobbe, G. / Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. In: Bone Marrow Transplantation. 2005 ; Vol. 35, No. 11. pp. 1089-1093.
@article{247fcccf80d44cf0b6b30d8be4cb314c,
title = "Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings",
abstract = "The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings. Mycophenolate Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited. We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n = 33), myelodysplastic syndrome (MDS) (n = 3), acute lymphoblastic leukemia (ALL) (n = 20) or chronic myeloid leukemia (n = 37) who received CSA/MMF (n = 26) or CSA/MTX (n = 67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings. No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD. Time to myeloid recovery was significantly shorter in patients who received CSA/MMF. We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings.",
keywords = "Cyclosporine, GVHD, Methotrexate, Mycophenolate Mofetil, Stem cell transplantation",
author = "F. Neumann and T. Graef and C. Tapprich and M. Vaupel and Steidl, {Ulrich G.} and U. Germing and R. Fenk and A. Hinke and R. Haas and G. Kobbe",
year = "2005",
month = "6",
doi = "10.1038/sj.bmt.1704956",
language = "English (US)",
volume = "35",
pages = "1089--1093",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

AU - Neumann, F.

AU - Graef, T.

AU - Tapprich, C.

AU - Vaupel, M.

AU - Steidl, Ulrich G.

AU - Germing, U.

AU - Fenk, R.

AU - Hinke, A.

AU - Haas, R.

AU - Kobbe, G.

PY - 2005/6

Y1 - 2005/6

N2 - The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings. Mycophenolate Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited. We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n = 33), myelodysplastic syndrome (MDS) (n = 3), acute lymphoblastic leukemia (ALL) (n = 20) or chronic myeloid leukemia (n = 37) who received CSA/MMF (n = 26) or CSA/MTX (n = 67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings. No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD. Time to myeloid recovery was significantly shorter in patients who received CSA/MMF. We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings.

AB - The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings. Mycophenolate Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited. We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n = 33), myelodysplastic syndrome (MDS) (n = 3), acute lymphoblastic leukemia (ALL) (n = 20) or chronic myeloid leukemia (n = 37) who received CSA/MMF (n = 26) or CSA/MTX (n = 67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings. No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD. Time to myeloid recovery was significantly shorter in patients who received CSA/MMF. We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings.

KW - Cyclosporine

KW - GVHD

KW - Methotrexate

KW - Mycophenolate Mofetil

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=20044386782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044386782&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704956

DO - 10.1038/sj.bmt.1704956

M3 - Article

C2 - 15821769

AN - SCOPUS:20044386782

VL - 35

SP - 1089

EP - 1093

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -